---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-042078"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:52:21.842580+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Absci announces strategic R&D partnership with PrecisionLife to develop AI-enabled drug pipeline

## Summary
- Partnership combines Absci's generative AI antibody design with PrecisionLife's disease biology to develop up to five drug targets.
- With this partnership, Absci has signed ten new Active Programs in 2023, achieving its full-year outlook.
- Collaboration aims to create a shared pipeline of novel biotherapeutics for chronic diseases with unmet medical needs.
- Absci and PrecisionLife will jointly evaluate options to advance programs and share in potential value.

## SEC filing metadata
- accession: 0001628280-23-042078
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828023042078/0001628280-23-042078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828023042078/absc-20231220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-042078
- JSON: https://secwatch.observer/filing/0001628280-23-042078.json
- Plain text: https://secwatch.observer/filing/0001628280-23-042078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.